TY - JOUR
T1 - Therapeutic effect of vitamin d supplementation in a pilot study of crohn's patients
AU - Yang, Linlin
AU - Weaver, Veronika
AU - Smith, Jill P.
AU - Bingaman, Sandra
AU - Hartman, Terryl J.
AU - Cantorna, Margherita T.
N1 - Funding Information:
Guarantor of the article: Margherita T. Cantorna Specific author contributions: L.Y., V.W., and S.B. collected and analyzed the data; L.Y. wrote the manuscript; V.W. and S.B. supervised the study; J.P.S., T.J.H., and M.T.C. conceived and directed the project, secured funding, and edited the manuscript. Financial support: GCRC funding NIH M01 RR010732 and C06-RR016499 and the Clinical and Translational Science Pilot Project Awards, College of Medicine, Hershey PA. This project is funded, in part, under a grant with the Pennsylvania Department of Health using Tobacco CURE Funds. The Department specifically disclaims responsibility for any analyses, interpretations, or conclusions. Potential competing interests: None.
PY - 2013
Y1 - 2013
N2 - OBJECTIVES: Low vitamin D status may be associated with Crohn's disease. A pilot study was performed in patients with mild-to-moderate Crohn's disease to determine the dose of vitamin D needed to raise serum vitamin D levels above 40 ng/ml. METHODS: Patients were evaluated for severity of symptoms using the Crohn's disease activity index (CDAI) and patients with mild-to-moderate (150-400 CDAI scores) Crohn's disease were entered into the study (n=18). Vitamin D3 oral therapy was initiated at 1,000 IU/d and after 2 weeks, the dose was escalated incrementally until patients' serum concentrations reached 40 ng/ml 25(OH)D3 or they were taking 5,000 IU/d. Patients continued on the vitamin D supplements for 24 weeks. CDAI, quality of life measures, bone mineral density, dietary analyses, cytokines, parathyroid hormone, calcium, and several other laboratory measurements were evaluated at baseline and after 24 weeks supplementation. RESULTS: Fourteen of eighteen patients required the maximal vitamin D supplement of 5,000 IU/d. Vitamin D oral supplementation significantly increased serum 25(OH)D3 levels from 16±10 ng/ml to 45±19 ng/ml (Po<.0001) and reduced the unadjusted mean CDAI scores by 112±81 points from 230±74 to 118±66 (Po<.0001). Quality-of-life scores also improved following vitamin D supplementation (P=0.0004). No significant changes in cytokine or other laboratory measures were observed. CONCLUSIONS: Twenty-four weeks supplementation with up to 5,000 IU/d vitamin D3 effectively raised serum 25(OH)D3 and reduced CDAI scores in a small cohort of Crohn's patients suggesting that restoration of normal vitamin D serum levels may be useful in the management of patients with mild-moderate Crohn's disease.
AB - OBJECTIVES: Low vitamin D status may be associated with Crohn's disease. A pilot study was performed in patients with mild-to-moderate Crohn's disease to determine the dose of vitamin D needed to raise serum vitamin D levels above 40 ng/ml. METHODS: Patients were evaluated for severity of symptoms using the Crohn's disease activity index (CDAI) and patients with mild-to-moderate (150-400 CDAI scores) Crohn's disease were entered into the study (n=18). Vitamin D3 oral therapy was initiated at 1,000 IU/d and after 2 weeks, the dose was escalated incrementally until patients' serum concentrations reached 40 ng/ml 25(OH)D3 or they were taking 5,000 IU/d. Patients continued on the vitamin D supplements for 24 weeks. CDAI, quality of life measures, bone mineral density, dietary analyses, cytokines, parathyroid hormone, calcium, and several other laboratory measurements were evaluated at baseline and after 24 weeks supplementation. RESULTS: Fourteen of eighteen patients required the maximal vitamin D supplement of 5,000 IU/d. Vitamin D oral supplementation significantly increased serum 25(OH)D3 levels from 16±10 ng/ml to 45±19 ng/ml (Po<.0001) and reduced the unadjusted mean CDAI scores by 112±81 points from 230±74 to 118±66 (Po<.0001). Quality-of-life scores also improved following vitamin D supplementation (P=0.0004). No significant changes in cytokine or other laboratory measures were observed. CONCLUSIONS: Twenty-four weeks supplementation with up to 5,000 IU/d vitamin D3 effectively raised serum 25(OH)D3 and reduced CDAI scores in a small cohort of Crohn's patients suggesting that restoration of normal vitamin D serum levels may be useful in the management of patients with mild-moderate Crohn's disease.
UR - http://www.scopus.com/inward/record.url?scp=84885743052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885743052&partnerID=8YFLogxK
U2 - 10.1038/ctg.2013.1
DO - 10.1038/ctg.2013.1
M3 - Article
C2 - 23594800
AN - SCOPUS:84885743052
SN - 2155-384X
VL - 4
JO - Clinical and Translational Gastroenterology
JF - Clinical and Translational Gastroenterology
M1 - e33
ER -